Newswise - Adding to the long list of the benefits of aspirin, researchers have found that it is responsible for reducing toxic bacteria associated with serious infections. A study led by Dartmouth Medical School describes how salicylic acid - produced when the body breaks down aspirin - disrupts the bacteria's ability to adhere to host tissue, reducing the threat of deadly infections.
The investigation, which appears in a recent issue of the Journal of Clinical Investigation, focused on the bacterium Staphylococcus aureus, and its role in infections in animal tissue. S. aureus is a leading cause of serious systemic (often referred to as staph) infections and abscesses.
"Our research shows that salicylic acid, a byproduct of aspirin, impacted the stress system of the bacteria and reduced its ability to cause infection," said lead author Dr. Ambrose Cheung, a professor of microbiology and immunology at Dartmouth Medical School.
By disrupting this stress system, aspirin reduced the bacteria's capacity to adhere to host tissue. In addition, the salicylic acid disrupted the ability of S. aureus to produce toxins, which the bacteria require to propagate and spread to other tissue. As a result, the animals treated with aspirin have smaller abscesses and they have fewer number of bacteria in the infection. Aspirin did not cure it, notes Cheung, but it reduced the ability of the bacteria to cause infection.
The S. aureus bacteria are also responsible for sepsis, a blood poisoning disease that strikes 750,000 people in the US annually and is the leading cause of death in America's non-coronary intensive care units. Cases of sepsis are growing in number each year and are becoming increasingly resistant to antibiotics, making aspirin a possibly invaluable option for treatment.
"The fact that aspirin has been used for pain treatment, to reduce morality due to heart attacks, and can possibly reduce the risks of infection is incredible," said Cheung. "We look forward to conducting future tests with aspirin in conjunction with antibiotic therapy."
Source: Dartmouth-Hitchcock Medical Center
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.